High impact information on Anquil

• METHODS: To address this phenomenon in a clinical study, we investigated the D2 dopamine receptor binding in 15 DSM-III-R schizophrenics in the drug-naive state and 3 days after completion of a standardized neuroleptic therapy (benperidol 12-16 mg/day, for 25 days) using single photon emission computed tomography (SPECT) [1].
• Complete dopamine D2 receptor occupancy without extrapyramidal side effects under benperidol [2].
• In this study we investigate the kinetics of the 3,4-dihydroxyphenylethylamine (dopamine) receptor-ligand binding using PET data from a series of experiments in the baboon with the 18F-labeled drugs spiperone, haloperidol, and benperidol [3].
• Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application [4].
• Droperidol, benperidol and bromperidol, all potent neuroleptic drugs, failed (at 10(-9) M) to potentiate salivation [5].

Biological context of Anquil

• Pharmacokinetics of benperidol in volunteers after oral administration [6].
• Report of the committee on instrumentation and procedures in visual electrophysiology at the request of the Concilium Ophthalmologicum Universale [7].

Associations of Anquil with other chemical compounds

• Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in schizophrenic patients [8].

Gene context of Anquil

• The compounds that share structural elements with N-methylspiperone and benperidol bind non-selectively to the D2 and D3 dopamine receptor subtypes [9].

Analytical, diagnostic and therapeutic context of Anquil

• Pharmacokinetics and bioavailability of benperidol were determined in 13 schizophrenic patients after acute administration of 6 mg benperidol as an intravenous (i.v.) bolus injection, orally as liquid, and orally as tablets using a partially randomized cross-over design [4].
• 3N-(2'-[18F]Fluoroethyl)benperidol ([18F]FEB) an 18F-labeled analogue of the D2 antagonist benperidol, was evaluated as a tracer for positron emission tomography (PET) [10].
• Determination of benperidol in human plasma by high-performance liquid chromatography [11].
• High-dosage neuroleptic therapy for acute schizophrenic patients--two double-blind studies with benperidol [12].
• Electrochemical detection of benperidol in serum for drug monitoring in humans [13].

References